International Multicentric Study ARON-1
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospital of Macerata
About this trial
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.
Two Supplementary Studies (ARON-1α and ARON-1β) have been designed. The ARON-1α Supplementary Study has been designed to investigate for the presence of genomic signatures from tumor samples of patients treated with first-line immuno-combinations for advanced RCC. The ARON-1β Supplementary Study has been designed to charaterize the immune cell populations and assess their relationship with the clinical outcome of mRCC patients treated with first-line immuno-combinations
Eligibility criteria
Qualifiers
Patients aged >18y
Cytological or Histologically confirmed diagnosis of clear cell or non-clear cell RCC
Histologically or radiologically confirmed diagnosis of metastatic disease
First-line treatment with nivolumab plus ipilimumab or nivolumab plus cabozantinib or pembrolizumab plus axitinib or pembrolizumab plus lenvatinib or avelumab plus axitinib or atezolizumab plus bevacizumab
Disqualifiers
Patients without histologically confirmed diagnosis of RCC
Patients without histologically or radiologically confirmed metastatic disease
Patients treated with immuno-combinations not included in the list reported in the Inclusion Criteria Section
Trial design
Treatments tested in this trial
- pembrolizumab plus axitinib
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov